Renalytix Plc (RNLX)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Renalytix Plc (“Renalytix” or the “Company) (NASDAQ: RNLX). Investors who purchased Renalytix securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Renalytix and certain of its officers and/or directors have violated federal securities laws.
On or around July 17, 2020, Renalytix conducted its initial public offering, issuing 11 million of its ordinary shares to the public at $13.50 per share. Then, on March 31, 2022, Renalytix announced its financial results for the second quarter of its fiscal year 2022. Among other results, the Company reported second quarter GAAP earnings per share of -$0.21, missing consensus estimates by $0.04, and revenue of $0.84 million, missing consensus estimates by $0.21 million. Renalytix also reported that during the three and six months ended December 31, 2021, the Company recorded a loss of $1.4 million and $2 million, respectively, to adjust its investment in a subsidiary, Verici Dx Limited, to fair value. On this news, Renalytix’s ordinary share price fell $0.21 per share, or 2.95%, to close at $6.92 per share on March 31, 2022.
If you are aware of any facts relating to this investigation or purchased Renalytix shares you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.